Medtech stocks benefit as drug-pricing scrutiny intensifies
December 02, 2015 at 13:23 PM EST
NEW YORK, Dec 2 (Reuters) - Investors have been moving into medical device shares as a safer play in the healthcare sector amid concerns that intensifying scrutiny over high U.S. prescription drug prices will continue to weigh on pharmaceutical and biotech stocks.